Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.61 |
| ▸ | AR | P10275 | 13/20 | 0.57 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26802462 | 0.89 | PGR (0.61) | PGRARSCN9ATNKSPARP1 | |
| SCHEMBL26805228 | 0.88 | PGR (0.52) | PGRARBCL2A1SCN9ATNKS | |
| SCHEMBL26802951 | 0.88 | AR (0.66) | PGRARSCN9AACACB | |
| SCHEMBL24031407 | 0.87 | PGR (0.57) | PGRARBCL2A1SCN9ATNKS | |
| SCHEMBL26802927 | 0.85 | AR (0.69) | PGRAR | |
| SCHEMBL26805352 | 0.84 | AR (0.53) | PGRARSCN9A | |
| SCHEMBL26802931 | 0.83 | AR (0.57) | PGRAR | |
| SCHEMBL24298588 | 0.82 | PGR (0.60) | PGRARBCL2A1TNKSPARP1 | |
| SCHEMBL24298723 | 0.82 | PGR (0.60) | PGRARBCL2A1TNKSPARP1 | |
| SCHEMBL31061235 | 0.82 | PGR (0.60) | PGRARBCL2A1TNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | PGR 62/4885AR 1/4885BCL2A1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.